We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Some of the world’s biggest health challenges do not lend themselves to conventional investment
Experts believe bacteriophages could be crucial extra tool
Manufacturers struggle to keep pace with post-pandemic demand as dozens of countries report low supply of drugs
Medicines are often given for viral infections such as flu, for which they are useless, but can cause side effects
Few countries have well funded plans to tackle health threat to millions
Industry cautiously optimistic amid bipartisan support for US Pasteur bill
Despite pledges to learn the lessons of Covid-19, caution is already waning. Plus: crisis turned a spotlight on healthcare services; climate change and urbanisation drive rise in ‘zoonotic’ illnesses; return of polio to US highlights impact of anti-vax campaigners
Monitoring the health of cattle lowers the use of drugs — and the risk of bacterial resistance to them
Just one drug remains effective for the sexually transmitted disease but soon the bacteria may be able to evade it
Fast-growing food sector has become a test case for the use and abuse of the drugs
Infected wounds are growing cause for concern in the Middle East, Ukraine and beyond
Prevention is better than cure — but is too costly for some countries where drug-resistant bacteria are rampant
Identifying conditions can prevent inappropriate drug use, but there are barriers to progress in poorer regions
Global co-operation is desperately needed to overcome threat from drug-resistant infections
Broader funding, registration and stewardship is pivotal to making the antibiotic market more sustainable
Study finds lower middle income countries in South Asia and Latin America have highest levels of pollutants
Move could boost global development of drugs to ease antimicrobial resistance
Fixed fee aims to incentivise pharma groups to develop new drugs and curb overprescription
Drug-resistant pathogens and poor hygiene mean simple procedures can deteriorate into lengthy and costly infections
New drugs are needed as resistance grows but plans to improve incentives are too modest, executives say
To save lives and economies, we must make progress by drawing on lessons from Covid-19
Research underscores the dangers of bacteria developing the ability to resist drugs
FT dashboard tracks responses to the growing threat of antimicrobial resistance
Political will is needed to address absence of sufficient financial incentives for new drugs
Failure to ensure they reach world’s poorest increases health risks, says pharma body
International Edition
